Scarica l'app Stockscreener
54.50
1.11%
-0.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRUS Giù?
Forum
Previsione
Precedente Chiudi:
$55.11
Aprire:
$54.91
Volume 24 ore:
315.84K
Relative Volume:
0.28
Capitalizzazione di mercato:
$4.10B
Reddito:
$35.93M
Utile/perdita netta:
$-244.56M
Rapporto P/E:
-13.80
EPS:
-3.95
Flusso di cassa netto:
$-157.31M
1 W Prestazione:
+1.26%
1M Prestazione:
-1.00%
6M Prestazione:
+24.29%
1 anno Prestazione:
-2.40%
Intervallo 1D:
$53.92
$55.23
Intervallo di 1 settimana:
$51.78
$55.30
Portata 52W:
$33.19
$62.98
Merus N V Stock (MRUS) Company Profile
Nome
Merus N V
Settore
Industria
Telefono
31 030 253 8800
Indirizzo
YALELAAN 62, 3584 CM UTRECHT
Confronta MRUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
54.50 | 4.10B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-02-07 | Iniziato | Wells Fargo | Overweight |
| 2024-11-21 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-03-28 | Iniziato | Truist | Buy |
| 2024-03-04 | Reiterato | Needham | Buy |
| 2023-11-02 | Iniziato | Canaccord Genuity | Buy |
| 2023-08-21 | Iniziato | TD Cowen | Outperform |
| 2022-08-02 | Iniziato | Stifel | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Needham | Buy |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-06-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-08 | Iniziato | William Blair | Outperform |
| 2021-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-27 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Ripresa | Guggenheim | Buy |
| 2019-06-28 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Ripresa | Guggenheim | Buy |
| 2019-04-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-03-21 | Downgrade | Citigroup | Buy → Neutral |
| 2016-12-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2016-06-13 | Iniziato | Citigroup | Buy |
| 2016-06-13 | Iniziato | Guggenheim | Buy |
| 2016-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Merus N V Borsa (MRUS) Ultime notizie
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - Yahoo Finance
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey
Merus N.V. (MRUS): A Breakthrough in Oncology with Petosemtamab's ASCO-Backed Potential - AInvest
Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
(MRUS) Technical Data - news.stocktradersdaily.com
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com Nigeria
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
Merus N.V. announces proposed public offering of common shares - MSN
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus Announces Public Offering of Common Shares - TipRanks
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
MRUS: Joint Managers Lead Successful Offering | MRUS Stock News - GuruFocus
Merus Prices $300 Million Stock Offering - marketscreener.com
Merus N.V. (MRUS) Launches $300M Public Offering - GuruFocus
Merus N.V. announces public offering of common shares By Investing.com - Investing.com South Africa
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln - Nasdaq
Merus N.V. Announces Pricing of Public Offering of Common Shares - The Manila Times
Merus N.V. Announces Proposed Public Offering of Common Shares | - GuruFocus
Merus (MRUS) Initiates Public Offering to Fund Development | MRU - GuruFocus
Merus (MRUS) Initiates Public Offering to Fund Development | MRUS Stock News - GuruFocus
Merus N.V. announces public offering of common shares - Investing.com Australia
Merus Plans Public Share Offering - marketscreener.com
Drugmaker Merus slips after share offering launch - TradingView
Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire
How to Take Advantage of moves in (MRUS) - news.stocktradersdaily.com
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? - Benzinga
Merus, N.V. Provides Updates on Clinical Development - marketscreener.com
Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News
Merus Announces Promising Phase 2 Trial Results - TipRanks
ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer - Yahoo Finance
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan
Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com
Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Merus N V Azioni (MRUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Merus N V Azioni (MRUS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 09 '25 |
Option Exercise |
18.61 |
6,695 |
124,594 |
6,695 |
| Silverman Peter B. | COO & GC |
Jul 10 '25 |
Sale |
55.00 |
16,805 |
924,275 |
0 |
| Silverman Peter B. | COO & GC |
Jul 09 '25 |
Sale |
55.00 |
6,695 |
368,225 |
0 |
2.10%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):